Literature DB >> 3018580

Olfactory dysfunction in humans with deficient guanine nucleotide-binding protein.

R S Weinstock, H N Wright, A M Spiegel, M A Levine, A M Moses.   

Abstract

The guanine nucleotide-binding stimulatory protein (Gs) couples hormone-receptor interaction to the activation of adenylate cyclase and the generation of cyclic AMP. Studies using frog neuroepithelium indicate that the sense of smell is mediated by a Gs-adenylate cyclase system, and this prompted us to test olfaction in the only known model of Gs deficiency in the animal kingdom, Gs-deficient (type 1a) pseudohypoparathyroidism (PHP), which occurs in humans. Such patients are resistant to the cAMP-mediated actions of several hormones. (Although Henkin has reported disturbances in the sense of smell in six patients with PHP, currently available biochemical measurements such as the cAMP response to parathyroid hormone (PTH) and determination of Gs activity were not reported and olfactory testing was limited.) In the present study, we found that all Gs-deficient patients had impaired olfaction when compared with PHP patients who had normal Gs activity (type 1b PHP, in which patients are resistant only to the action of PTH in the kidney). This is the first evidence of human olfactory impairment which can be related to Gs deficiency and suggests that Gs-deficient PHP patients may be resistant to cAMP-mediated actions in other non-endocrine systems.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018580     DOI: 10.1038/322635a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  8 in total

1.  Components of the intracellular cAMP system supporting the olfactory reception of amyl alcohol.

Authors:  E V Bigdai; V O Samoilov
Journal:  Neurosci Behav Physiol       Date:  2003-01

2.  Genetic deficiency of the alpha subunit of the guanine nucleotide-binding protein Gs as the molecular basis for Albright hereditary osteodystrophy.

Authors:  M A Levine; T G Ahn; S F Klupt; K D Kaufman; P M Smallwood; H R Bourne; K A Sullivan; C Van Dop
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

Review 3.  Nonclassic features of pseudohypoparathyroidism type 1A.

Authors:  Ashley H Shoemaker; Harald Jüppner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 4.  Albright's hereditary osteodystrophy.

Authors:  L C Wilson; R C Trembath
Journal:  J Med Genet       Date:  1994-10       Impact factor: 6.318

5.  Extensive cerebral calcification and retinal changes in pseudohypoparathyroidism.

Authors:  E Ellie; J Julien; X Ferrer; I Riss; M C Durquety
Journal:  J Neurol       Date:  1989-10       Impact factor: 4.849

6.  Glucose Homeostasis and Energy Balance in Children With Pseudohypoparathyroidism.

Authors:  Katia M Perez; Kathleen L Curley; James C Slaughter; Ashley H Shoemaker
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

7.  Pseudohypoparathyroidism, parkinsonism syndrome, with no basal ganglia calcification.

Authors:  B K Evans; D K Donley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

Review 8.  Management of pseudohypoparathyroidism.

Authors:  Emily L Germain-Lee
Journal:  Curr Opin Pediatr       Date:  2019-08       Impact factor: 2.856

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.